Search This Blog

Friday, July 17, 2026

You've Heard of Cyclospora. What Other Parasites Can You Catch From Food?

 As health officials track cyclosporiasis cases in multiple states, experts note that there are plenty of other parasites that people can contract from food.

These fall into two main categories: protozoa -- like Cyclospora, the one causing "explosive diarrhea" right now -- and worms.

In the U.S., some of the most common foodborne parasites include Cryptosporidium spp., Giardia intestinalis, Cyclospora cayetanensis, and Toxoplasma gondii (all protozoa), as well as roundworms like Trichinella spp. and Anisakis spp., and tapeworms like Diphyllobothrium spp. and Taenia spp., according to the CDC.

"Protozoa will cause much more severe diarrhea," David Freedman, MD, professor emeritus of infectious diseases at the University of Alabama at Birmingham and spokesperson for the Infectious Diseases Society of America, told Medpage Today. "Worms can do other things because [they] can escape from the intestinal tract and end up in the liver and start blocking movements of fluids just because they're so physically big."

Indeed, Cryptosporidium spp., G. intestinalis, and C. cayetanensis "most commonly cause diarrhea and other gastrointestinal symptoms," according to the CDC. Meanwhile, worms can lead to abdominal pain, diarrhea, muscle pain, cough, skin lesions, malnutrition, weight loss, neurological and many other symptoms "depending on the particular organism and burden of infection."

Humans can become infected with tapeworms, like the pork tapeworm Taenia solium, as well as beef tapeworms (Taenia saginata) by eating raw or undercooked meat, experts said. Symptoms are typically mild or nonexistent, according to the CDC, but T. solium infections can lead to cysticercosis, a disease that can cause seizures.

Joel Barratt, PhD, a molecular parasitologist and assistant professor at Emory School of Medicine in Atlanta, who previously led the CDC laboratory team focused on Cyclospora outbreak response, told MedPage Today that if pork tapeworm larvae are consumed, "you can end up with neurocysticercosis, where the worms basically travel around your body [and] end up in your brain."

HHS Secretary Robert F. Kennedy, Jr. famously said that doctors found the remains of a worm in his brain, which some experts have since surmised may have been larva from T. solium.

Though many infections from foodborne parasites are self-limiting, they can lead to serious outcomes, especially in the very young, the very old, and immunocompromised individuals, experts said.

One unique example is T. gondii, which is "possibly the most successful parasite on the planet," Barratt said.

"Toxoplasma doesn't typically cause disease" in people with a healthy immune system, he said, "though it can." Physicians routinely warn pregnant individuals about exposure to Toxoplasma -- typically through cleaning cat litter boxes -- because it can cause serious birth defects in the baby.

A newly infected mother can pass the infection to their unborn child, and people can contract the parasite through consumption of undercooked meat or shellfish, unwashed contaminated fresh produce, as well as accidental consumption via contact with cat feces (like from a cat litter box) or contaminated soil, according to the CDC.

As for roundworms, Anisakis is very common in fish, Sean Murphy, MD, PhD, chief of pathology and laboratory medicine at Seattle Children's Hospital and professor at the University of Washington, told MedPage Today. "The risk factors for that are eating sushi or ceviche."

"Often the story is, caught by an individual and prepared as opposed to coming through the supply chain that has rigorous inspections," he explained. "In fact, commercial freezing of fish is a great safety factor in preventing some of these worms from having more impact."

Trichinella, for instance, has been associated with wild game, Murphy noted. When hunters hunt for their own meat, "wild animals can have these organisms, and because they don't come through the USDA [U.S. Department of Agriculture] food supply chain that is inspected, sometimes if its undercooked -- for example, on the barbecue -- some of these can make their way into patients."

"A hundred years ago, that was more common, before we had USDA food safety practices," he said.

Often, the emergency department is the first healthcare encounter for people who may have contracted a foodborne parasite, and this helps with public health surveillance, experts noted.

"There are a variety of emergency departments around the country that the CDC collects data from to track and to see if there are increased visits for symptoms that could be suggestive of really any infection," Arjun Venkatesh, MD, MBA, MHS, chair of emergency medicine at Yale School of Medicine, told MedPage Today. "It could be the flu and COVID in the winter," he said. "It could be these types of parasites. And so we're sort of at the tip of the spear."

However, "there's not rapid testing available in the emergency department," Venkatesh noted. "In the case of most parasites, often we see people with symptoms like diarrhea or vomiting, and we're trying to figure out, based on either their history and what they tell us, or what's going on and what we know from public health data, whether or not this person's symptoms could be caused by a parasite or not," he said.

"It matters because some parasites are treated," Venkatesh said. For instance, in the case of the current outbreak, Cyclospora can be treated with the antibiotic trimethoprim-sulfamethoxazole. "However, often, you're treating a parasite to shorten its duration. Or in a high-risk person, somebody who's older or immunocompromised, it might reduce the chance they are hospitalized."

For most people -- and for most parasites -- the patient is going to get better on their own, he said.

But experts emphasized key steps to protect against foodborne parasites.

Food hygiene and handwashing are essential, Freedman said. Also, "be on the lookout for outbreaks, news of outbreaks we're having now, where certain foods are contaminated," he said, noting that "cooking kills most things."

"If you're going to eat steak tartare and [other] raw meat," Freedman said, "that's going to increase your chances of a few of these things."

Overall, "most foodborne illness in the U.S. is caused by bacteria and viruses," Murphy acknowledged. "Parasites are much less common," however, they "also require specialized testing," he said. "They sometimes are much more environmentally hardy, so they can persist in the environment. Sometimes they can also cause prolonged disease, and that makes them harder to trace than some of the viral and bacterial things that we've come to know better in the U.S."

The ongoing cyclosporiasis outbreak "highlights the importance of the public health system in the U.S.," he said. This consists of a "coordinated network of state public health labs and the CDC, and very strong food safety requirements."

"When that works, nobody talks about how great it is, and it's working now to try to zero in and find basically two grains of sand on a whole football field to figure out where this thing came from," Murphy said. It's important that this system continues to be supported, he noted. "It's a really important part of why we have such a great food supply, and it's to the benefit of everyone."

https://www.medpagetoday.com/publichealthpolicy/publichealth/122230

GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail

 

Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.

GSK will no longer invest in the development of camlipixant in chronic cough after a disappointing late-stage performance.

The pharma had been running the Phase 3 CALM-1 and CALM-2 trials, which tested a 52-week and 24-week course of camlipixant, respectively. CALM-1 met a primary endpoint, GSK said on Friday, with a 50-mg dose significantly lowering 24-hour cough frequency at 12 weeks versus placebo.

Camlipixant failed CALM-2, however, with no significant decrease in cough frequency occurring. Both trials missed key secondary endpoints, according to GSK.

With this efficacy profile, camlipixant “is unlikely to transform patient care,” GSK said in its release, adding that it will no longer develop the drug for refractory chronic cough (RCC). The pharma will continue to study the drug for irritable bowel syndrome, for which it is in mid-stage development.

Camlipixant, an orally available blocker of the P2X3 receptor, was originally discovered and developed by Bellus Health, which GSK acquired in April 2023 for $2 billion.

P2X3 receptors are expressed by nerves on airways, which are present at a much higher density than usual in patients with refractory chronic cough. By blocking the P2X3 cascade, camlipixant is supposed to work by normalizing cough reflex and frequency.

At the time of the acquisition, GSK was in a cough contest with Merck, which was developing another P2X3 antagonist called gefapixant—a drug that had already been rebuffed by the FDA once. In January 2022, the agency had rejected gefapixant’s application in refractory chronic cough for issues unrelated to safety, though the pharma at the time did not provide further details.

In December 2023, months after GSK’s buyout of Bellus, Merck’s gefapixant again failed to secure a U.S. approval, with the FDA saying the drug package “did not meet substantial evidence of effectiveness.” Currently, Merck sells the drug as Lyfnua in several European countries and Japan.

For GSK, the decision to discontinue camlipixant in RCC follows the termination of its partnership with Alector, effective Jan. 2, 2027. The companies first linked up in July 2021 to advance two antibodies for neurodegenerative conditions. Both assets failed in the clinic, leading to the pharma’s decision to abandon Alector. At the time, GSK paid $700 million upfront and earmarked up to $1.5 billion in possible milestones for the biotech.

https://www.biospace.com/business/gsk-culls-cough-program-for-drug-at-the-heart-of-2b-bellus-bet-after-phase-3-fail

Insmed moves closer to $6B opportunity as PAH drug shows long-term durability

 

Insmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements through one year of follow-up.

Insmed’s investigational therapy sustained functional and biomarker improvements through 12 months in an open-label extension study of patients with pulmonary arterial hypertension.

These benefits “strengthen the case” for Insmed’s drug candidate, called treprostinil palmitil inhalation powder (TPIP), “as the best-in-class inhaled prostanoid,” analysts at Guggenheim Partners told investors in a Thursday note. The firm projects peak TPIP sales to top $6 billion across several planned indications, including pulmonary arterial hypertension (PAH).

The extension study includes more than 90 patients with PAH who were already on daily TPIP from lead-in studies, as well as those who were transitioning to the inhaled therapy from placebo. The study was designed to follow participants through 24 months.

Twelve-month data presented on Thursday demonstrated functional improvements as measured by the 6-minute walk distance (6MWD). Those who maintained ongoing TPIP treatment saw a 55.7-meter increase in 6MWD, while distance grew by 54.1 meters in those who crossed over from placebo.

NT-proBNP, a biomarker indicative of heart strain, dropped by roughly 60% in both groups, Insmed said.

Guggenheim called these findings “impressive,” adding that “we come away from this data release with incrementally higher confidence in the clinical profile of this product.” The firm nevertheless flagged some outstanding concerns, including the extension trial’s small sample size and the fact that “we are still multiple years away from any Phase 3 readout for TPIP.”

Another concern is what Truist Securities flagged as an “efficacy ceiling” associated with TPIP. “A key potential differentiator of TPIP is its ability to be titrated beyond the dosing limits of currently available inhaled prostacyclins,” the analysts said in a Thursday note. However, only around 21% of patients in the current study went above 640 µg, with just seven participants reaching the maximum allowable dose of 1,280 µg, according to Truist.

“It is unclear to us why physicians would not continue escalating in well-tolerating patients if meaningful incremental benefit existed,” the firm continued. “As such, the data leave open the question of whether TPIP reaches an efficacy ceiling around current dose levels” or if going beyond 640 µg still yields meaningful clinical benefit, Truist wrote.

Insmed has recently started the Phase 3 PALM-PAH study to assess once-daily TPIP in PAH patients over 24 weeks, the biotech said on Thursday, though it did not provide a specific timeline for a topline readout.

The TPIP data comes after Insmed in April axed the hidradenitis suppurative program for its recently approved DPP1 inhibitor Brinsupri following disappointing mid-stage data. Brinsupri was approved in August 2025 for non-cystic fibrosis bronchiectasis. In the first quarter, the drug made $207.9 million—an “impressive” figure that indicates the launch is “going very well,” Guggenheim wrote in a May 7 note.

https://www.biospace.com/drug-development/insmed-moves-closer-to-6b-opportunity-as-pah-drug-shows-long-term-durability

IRGC Targets US Command Center In Syria In Unprecedented Attack

 Iran's large-scale 'retaliation' on US bases and Gulf states overnight included a rare first if confirmed. The Islamic Revolutionary Guard Corps (IRGC) said it conducted a missile or drone attack on an American special operations command center at al-Tanf in Syria on Friday.

The action came after the US bombed Iran for a sixth consecutive night, and while Iranian targets have on several occasions reached into Jordan, it is unprecedented that the Iranians take active aim at sites within Syria.

The IRGC stated the attack was in retaliation for the killing of Iranian soldiers in Iranshahr, in southern Iran.

While the hit on Syria was reported in Reuters based on state media claims, the alleged Tanf strike hasn't been independently verified:

A Syrian military source told Reuters that Iran carried out an attack near al-Tanf, but it had not hit the base itself. There were no casualties or material damage, the source added. 

The episode is the first reported attack on Syria since the US-Israeli war on Iran began in late February.

And more: "The IRGC statement claimed that a radar system, multiple helicopters, and several US personnel were destroyed in the strike. Reuters reported that it has not yet been able to independently verify these claims."

While it is unprecedented or at least unusual for US bases in Syria to come under direct attack by Iran, Tanf base has on multiple occasions come under attack from Iran-aligned Iraqi paramilitaries, and other hostile actors both within Syria and Iraq.

US troops had long operated out of Tanf to pressure the Assad government as part of the long-running US-backed regime change project.

The US primarily trained the Syrian Free Army (FSA) in that remote desert area - which was an umbrella group of various factions, likely among them jihadists, armed and funded by Washington.

But when Assad was finally ousted in December 2024, replaced by an Al-Qaeda group founder (Jolani/Sharaa), this also put Iranian forces in rapid retreat from the country after an over decade-long proxy war.

Syria's new AQ-linked government has been trying to impress its backers by claiming to bust up Iran-Hezbollah axis arms shipments:

Iran, alongside Russia, had been a close military supporter of the Syrian army, but the Syrian government's collapse - along with the weaking of Hezbollah with the recent Israeli assassination of much of its leadership in Lebanon, caused most Russian and Iranian troops into a hasty and forced withdrawal.

https://www.zerohedge.com/geopolitical/irgc-targets-us-command-center-syria-unprecedented-attack

Musk Buys Florida-Based Energy Company

 by Jill McLaughlin via The Epoch Times,

Elon Musk has acquired a power company based in Jacksonville, Fla., paying $1 billion for the mobile gas-turbine provider as a possible solution to data center energy needs.

The Federal Trade Commission (FTC) lists Musk as the acquiring party, with New APR Energy, LLC listed as the acquired entity.

Neither party issued public statements on the deal that closed May 14. Local business news outlet Jacksonville Daily Record first reported on the news in June before it gained national media attention in recent days.

The potential cost of the deal was found in a separate filing with the U.S. Securities and Exchange Commission (SEC) in which Technologies Group reported selling its 5 percent non-voting stake in New APR Energy in a May 28 SEC report.

Duos said its sale generated $50.4 million in net proceeds, which implies the Musk deal was worth at least $1 billion.

Musk continues to invest in artificial intelligence (AI) development with the research company he founded, xAI, and its chatbot Grok.

His xAI company runs the Colossus data center in Tennessee, a $20 billion facility near a power plant site, where he has had to rent turbine units as he waits for grid power to the site.

New APR Energy owns and maintains a fleet of gas turbines with more than 1 gigawatt of power generation capacity, according to a statement from the company in January, when it expanded capacity.

The company has been delivering power to clients for more than 20 years, deploying its fleets “in as little as 30 to 90 days,” the statement said.

Musk’s purchase of the Florida company represents his second investment in the energy sector. In 2006, Musk helped fund SolarCity, a company founded by his cousins, Peter and Lyndon Rive, which grew to be the largest residential solar installer in the United States.

Tesla bought SolarCity in an all-stock deal worth about $2.6 billion in 2016 and turned it into Tesla Energy.

Tech expert and podcaster Aakash Gupta said Musk’s latest transaction exposed the AI industry’s current problems.

“What [Musk] bought tells you where the real bottleneck in AI is,” Gupta said in a July 16 post on X.

New APR Energy operates a fleet of mobile gas and diesel turbines with over 1 gigawatt of generation capacity—enough to power 750,000 homes at once.

The fleet, which was built for disaster response, arrives on trucks and can be delivered, installed, and commissioned in a month.

The fast set-up time makes sense for Musk, who has already lived through delays with xAI’s first Memphis plant, Gupta said.

“Environmental groups sued. The [Justice Department] intervened to keep the turbines running. He was renting the most important input to his most important company,” Gupta said. “So he bought the landlord. … Every AI lab can buy the same chips. Only one of them now owns a power plant fleet that ships by truck.”

New APR Energy and Tesla did not return requests for comments about the purchase by publication time.

https://www.zerohedge.com/energy/musk-buys-florida-based-energy-company

'Apollomics secures $2M bridge financing from CEO'

 

  • Apollomics (APLM) on Wednesday said that it has entered into a $2.0 million unsecured convertible promissory note with its Chairman and CEO Hung-Wen (Howard) Chen.
  • The company said the proceeds will be used for working capital, including supporting clinical development programs and general operations.
  • The note carries 0% interest and will automatically convert into equity upon a future financing of at least $10.0 million, at a 20% discount to the lowest share price in that round.
  • The transaction was approved by the company’s audit committee and board, with Chen abstaining.
  • APLM -5.36% premarket to $15.0.
  • Source: Press Release

Kalaris positive expanded Phase 1a data for TH103 in neovascular AMD

 

Kalaris Therapeutics reports positive expanded Phase 1a data for TH103 in neovascular AMD with sustained efficacy, no intraocular inflammation at 2.5 mg

  • Expanded Phase 1a trial used a single-ascending-dose design and evaluated TH103 2.5 mg after process improvements.